Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexandre V Hirayama

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
Transplantation and Cellular Therapy|August 2, 2025
Opportunities to Improve Antibiotic Stewardship, and Identification of Blood Biomarkers Associated with Bacteremia Following CAR-T Cell TherapySai Kit Ng, Patrick W Flaherty, Melissa Ancheta, et al.
Immunity|October 3, 2025
Eomesodermin<sup>+</sup> CD4<sup>+</sup> T cells are critical for curative immunotherapy outcomesPing Zhang, Françoise Haeseleer, Olivia G Waltner, et al.
Blood Advances|October 30, 2023
Timing of anti-PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphomaAlexandre V Hirayama, Erik L Kimble, Jocelyn H Wright, et al.
Blood|February 8, 2019
Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapyKevin A Hay, Jordan Gauthier, Alexandre V Hirayama, et al.
Transplantation and Cellular Therapy|April 9, 2023
Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell TherapyNicolas Gazeau, Emily C Liang, Qian Vicky Wu, et al.
Blood|September 23, 2020
Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignanciesJordan Gauthier, Evandro D Bezerra, Alexandre V Hirayama, et al.
Blood|February 21, 2019
The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cellsAlexandre V Hirayama, Jordan Gauthier, Kevin A Hay, et al.
Blood Advances|December 3, 2024
Development and validation of predictive models of early immune effector cell-associated hematotoxicityEmily C Liang, Jennifer J Huang, Andrew J Portuguese, et al.
Blood|February 12, 2025
Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphomaLaura Samples, Hossein Sadrzadeh, Matthew J Frigault, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Transplantation and Cellular Therapy|August 2, 2025
Opportunities to Improve Antibiotic Stewardship, and Identification of Blood Biomarkers Associated with Bacteremia Following CAR-T Cell TherapySai Kit Ng, Patrick W Flaherty, Melissa Ancheta, et al.
Immunity|October 3, 2025
Eomesodermin<sup>+</sup> CD4<sup>+</sup> T cells are critical for curative immunotherapy outcomesPing Zhang, Françoise Haeseleer, Olivia G Waltner, et al.
Blood Advances|October 30, 2023
Timing of anti-PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphomaAlexandre V Hirayama, Erik L Kimble, Jocelyn H Wright, et al.
Blood|February 8, 2019
Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapyKevin A Hay, Jordan Gauthier, Alexandre V Hirayama, et al.
Transplantation and Cellular Therapy|April 9, 2023
Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell TherapyNicolas Gazeau, Emily C Liang, Qian Vicky Wu, et al.
Blood|September 23, 2020
Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignanciesJordan Gauthier, Evandro D Bezerra, Alexandre V Hirayama, et al.
Blood|February 21, 2019
The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cellsAlexandre V Hirayama, Jordan Gauthier, Kevin A Hay, et al.
Blood Advances|December 3, 2024
Development and validation of predictive models of early immune effector cell-associated hematotoxicityEmily C Liang, Jennifer J Huang, Andrew J Portuguese, et al.
Blood|February 12, 2025
Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphomaLaura Samples, Hossein Sadrzadeh, Matthew J Frigault, et al.
Pageof 4